Shaanxi Panlong Pharmaceutical (SZ:002864) Zheng Quan Zhi Xing·2025-08-27 14:16Core Viewpoint - The financial report of Shaanxi Panlong Pharmaceutical Group Co., Ltd. for the first half of 2025 shows significant growth in revenue and net profit compared to the same period in 2024, indicating a positive trend in the company's financial performance [5][7][8]. Financial Performance - Total operating revenue for the first half of 2025 reached CNY 574,023,000.14, an increase from CNY 455,356,633.75 in the same period of 2024, representing a growth of approximately 26.0% [5][7]. - The net profit for the first half of 2025 was CNY 59,979,473.51, slightly up from CNY 59,435,447.41 in the first half of 2024, indicating a stable profit margin [7][8]. - Basic and diluted earnings per share remained consistent at CNY 0.57 for the first half of 2025, unchanged from the previous year [8]. Assets and Liabilities - Total assets increased to CNY 2,362,246,494.51 at the end of the first half of 2025, compared to CNY 2,280,023,009.54 at the beginning of the year, reflecting a growth of approximately 3.6% [3][4]. - Total liabilities rose to CNY 696,000,341.43, up from CNY 642,840,255.08, indicating an increase of about 8.3% [4][5]. - The total equity attributable to shareholders increased to CNY 1,664,436,104.93 from CNY 1,635,217,029.35, showing a growth of approximately 1.8% [4][5]. Cash Flow - The net cash flow from operating activities for the first half of 2025 was CNY 62,620,899.02, down from CNY 111,157,587.41 in the same period of 2024, indicating a decrease in cash generation from operations [9][10]. - Cash and cash equivalents at the end of the first half of 2025 were CNY 1,166,765,970.54, slightly down from CNY 1,169,375,189.16 at the beginning of the year [9][10]. Cost Structure - Total operating costs for the first half of 2025 were CNY 502,134,108.31, compared to CNY 391,905,428.80 in the same period of 2024, reflecting an increase of approximately 28.2% [7][8]. - The cost of goods sold was CNY 280,795,329.78, up from CNY 171,037,480.65, indicating a significant rise in production costs [7][8].